Relationship between serum osteocalcin and glycaemic variability in Type 2 diabetes
Relationship between serum osteocalcin and glycaemic variability in Type 2 diabetes
复制标题
DOI：
10.1111/j.1440-1681.2010.05463.x
复制
发表时间：
2011-01-01
影响因子：
2.9
通讯作者：
Jia, Wei-Ping
中科院分区：
文献类型：
--
作者：
Bao, Yu-Qian;Zhou, Mi;Jia, Wei-Ping
P > 1。最近的报道描述了骨钙素在葡萄糖代谢和血糖变异性中的作用，已被证明与糖尿病并发症风险增加有关。然而，骨钙素与血糖变异性之间的关系尚不清楚。本研究的目的是研究血清骨钙素与血糖变异性之间的关系，通过2型糖尿病（T2DM）患者的连续血糖监测（CGM）系统来确定。本研究招募了59名糖化血红蛋白（HbA1c）水平在7.0%至10.9%之间的T2DM患者。在基线和8周的降糖治疗（磺酰脲、磺酰脲+ α -葡萄糖苷酶抑制剂或胰岛素+二甲双胍联合治疗）后收集生化信息和CGM参数。与基线相比，血清骨钙素显著升高（P = 0.014），而与葡萄糖变异性相关的参数，包括血糖漂移的平均幅度（MAGE）和血糖值的标准差，在8周的治疗期后显著降低（P < 0.001）。基线时，血清骨钙素水平与空腹c肽水平（P = 0.004）和稳态模型β细胞功能评估（P = 0.048）呈正相关，而血清骨钙素水平与空腹血糖（P = 0.023）、糖化血红蛋白（P = 0.020）、糖化白蛋白（P = 0.019）和24小时平均血糖呈负相关（P < 0.001）。多元逐步回归分析表明，基线骨钙素是最能预测MAGE变化的单一参数（beta = -0.122; P = 0.039）。总之，血清骨钙素浓度随着血糖控制的改善而升高。在降糖治疗期间，高初始骨钙素水平与随后血糖变异性的改善有关。
P>1. Recent reports have described the role of osteocalcin in glucose metabolism and glycaemic variability has been proven to be associated with an increased risk of diabetes complications. However, the relationship between osteocalcin and glycaemic variability remains unclear. The aim of the present study was to examine the relationship between serum osteocalcin and glycaemic variability, as determined by a continuous glucose monitoring (CGM) system in patients with Type 2 diabetes mellitus (T2DM).2. Fifty-nine T2DM patients with glycosylated haemoglobin (HbA1c) levels between 7.0% and 10.9% were recruited to the present study. Biochemical information and CGM parameters were collected at baseline and after 8 weeks of antihyperglycaemic therapy (either sulphonylurea, sulphonylurea + an alpha-glucosidase inhibitor or insulin + metformin combination therapy).3. Compared with baseline, serum osteocalcin increased significantly (P = 0.014), whereas parameters related to glucose variability, including the mean amplitude of glycaemic excursions (MAGE) and the standard deviation of blood glucose values, decreased significantly (P < 0.001) after the 8 week treatment period. At baseline, there was a positive correlation between serum osteocalcin levels and fasting C-peptide levels (P = 0.004) and homeostatic model assessment of beta-cell function (P = 0.048), but a negative correlation between serum osteocalcin levels and fasting plasma glucose (P = 0.023), HbA1c (P = 0.020), glycated albumin (P = 0.019) and 24 h mean blood glucose (P < 0.001). Multiple stepwise regression analysis indicated that baseline osteocalcin was the single parameter that best predicted the change in MAGE (beta = -0.122; P = 0.039).4. In conclusion, serum osteocalcin concentrations increased with improved glucose control. High initial osteocalcin levels were associated with subsequent improvements in glucose variability during glucose-lowering treatment.